WUGEN Presents Updated Preclinical Data on Novel Allogeneic CAR-T Platform at ASH Annual Meeting

ST. LOUIS, Dec. 3, 2018 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced updated preclinical data that validates its off-the-shelf fratricide-resistant CAR-T platform.…

Read More

WUGEN Announces Exclusive License Agreement for CAR-T Therapy Technologies from Washington University in St. Louis

ST. LOUIS, Nov. 13, 2018 /PRNewswire/ --  WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that it has entered into an exclusive license agreement with Washington…

Read More

WUGEN Announces Presentations at American Society of Hematology Annual Meeting

ST. LOUIS, Nov. 1, 2018  /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that abstracts showcasing the WUGEN platform were accepted for an…

Read More